| 2025-02-05 17-09-19 | Pyrroloquinoline Quinone (PQQ) does not affect in vitro cell proliferation in β-Galactosidase (D-Galactosidase)-induced C2C12 mouse myoblast cells at concentrations of 25 nM, 50 nM, or 100 nM |
| 2025-02-05 17-11-44 | Pyrroloquinoline Quinone (PQQ) increases cellular differentiation in vitro in β-Galactosidase (D-Galactosidase)-induced C2C12 mouse myoblast cells at a concentration of 100 nM |
| 2025-02-05 17-01-43 | Pyrroloquinoline Quinone (PQQ) reduces β-Galactosidase (D-Galactosidase) expression in vitro in galactosidase-induced C2C12 mouse myoblast cells at a concentration of 100 nM |
| 2025-02-05 16-55-00 | Pyrroloquinoline Quinone (PQQ) can improve scores on the pole test in mice during aging at a dose of 20 mg/kg/day |
| 2025-02-05 16-57-58 | Pyrroloquinoline Quinone (PQQ) reduces Muscle Atrophy in aging mice at a dose of 20 mg/kg/day |
| 2025-02-05 16-52-35 | Pyrroloquinoline Quinone (PQQ) can improve hanging time during aging in mice at a dose of 20 mg/kg/day |